Inhibitory effects of a nutrient mixture on human testicular cancer cell line NT 2/DT matrigel invasion and MMP activity.
Current treatment of testicular cancer is associated with secondary malignancy, infertility, and cytotoxicity. Based on reported antimetastatic potential, we investigated the effect of a nutrient mixture (NM) containing lysine, proline, arginine, ascorbic acid, and green tea extract on human testis cancer cell line NT 2/DT by measuring cell proliferation/cytotoxicity, modulation of MMP-2 and MMP-9 secretion, and cancer cell invasive potential. Human testis cancer cells NT 2/DT (ATCC) were grown in DME medium. At near confluence, the cells were treated with NM dissolved in media and tested at 0,10, 50, and 100 microg/mL in triplicate at each dose. Cells were also treated with PMA 200 ng/mL to study enhanced secretion of MMP-9. Cell proliferation/cytotoxicity was evaluated by MTT assay, MMP activity by gelatinase zymography, and invasion through Matrigel. The nutrient mixture showed no significant effect on testis cancer cell growth. Zymography demonstrated secretion of MMP-2 by untreated human testis cancer cells and MMP-9 with PMA induction. NM inhibited secretion of both MMPs in a dose-dependent fashion with virtual total inhibition of MMP-9 at 100 microg/mL. Invasion of human testis cancer cells through Matrigel was reduced by 84% at 50 microg/mL and at 100 microg/mL (p = 0.004). NM significantly inhibited MMP secretion and matrix invasion in testicular cancer cells without toxic effect, indicating potential as an anticancer agent.
Roomi
M Waheed
MW
Cancer Division, Dr. Rath Research Institute, 1260 Memorex Drive, Santa Clara, CA, 95050, USA.
Ivanov
Vadim
V
Kalinovsky
Tatiana
T
Niedzwiecki
Aleksandra
A
Rath
Matthias
M
D000596:Amino Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage; D001120:Arginine / Q000008:administration & dosage / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D028241:Camellia sinensis; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003094:Collagen; D004338:Drug Combinations; D006801:Humans; D007797:Laminin; D008239:Lysine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D009361:Neoplasm Invasiveness; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D011392:Proline / Q000008:administration & dosage / Q000627:therapeutic use; D011509:Proteoglycans; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology
D000596:Amino Acids; D000970:Antineoplastic Agents; D000975:Antioxidants; D004338:Drug Combinations; D007797:Laminin; D061965:Matrix Metalloproteinase Inhibitors; D010936:Plant Extracts; D011509:Proteoglycans; C465546:green tea extract AR25; C059485:matrigel; D003094:Collagen; D001120:Arginine; D011392:Proline; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D008239:Lysine; D001205:Ascorbic Acid